203 related articles for article (PubMed ID: 20697382)
1. Wrong numbers?
Nat Biotechnol; 2010 Aug; 28(8):761. PubMed ID: 20697382
[No Abstract] [Full Text] [Related]
2. Public biotech 2009-the numbers.
Huggett B; Hodgson J; Lähteenmäki R
Nat Biotechnol; 2010 Aug; 28(8):793-9. PubMed ID: 20697401
[No Abstract] [Full Text] [Related]
3. Public biotechnology 2005--the numbers.
Lähteenmäki R; Lawrence S
Nat Biotechnol; 2006 Jun; 24(6):625-34. PubMed ID: 16763588
[TBL] [Abstract][Full Text] [Related]
4. Public biotech 2006 - the numbers.
Lähteenmäki R; Lawrence S
Nat Biotechnol; 2007 Jul; 25(7):729-37. PubMed ID: 17621294
[No Abstract] [Full Text] [Related]
5. The changing norms of the life sciences.
Shorett P; Rabinow P; Billings PR
Nat Biotechnol; 2003 Feb; 21(2):123-5. PubMed ID: 12560827
[No Abstract] [Full Text] [Related]
6. Biotech R&D still reeling.
Lawrence S
Nat Biotechnol; 2004 Sep; 22(9):1068. PubMed ID: 15340460
[No Abstract] [Full Text] [Related]
7. Public biotechnology 2002--the numbers.
Lähteenmäki R; DeFrancesco L
Nat Biotechnol; 2003 Jun; 21(6):607-12. PubMed ID: 12776143
[No Abstract] [Full Text] [Related]
8. State of biotech sector--2005.
Lawrence S
Nat Biotechnol; 2006 Jun; 24(6):603. PubMed ID: 16763577
[No Abstract] [Full Text] [Related]
9. Private biotech 2004--the numbers.
Hodgson J
Nat Biotechnol; 2006 Jun; 24(6):635-41. PubMed ID: 16763589
[TBL] [Abstract][Full Text] [Related]
10. Public biotech 2018-the numbers.
Morrison C; Lähteenmäki R
Nat Biotechnol; 2019 Jul; 37(7):714-721. PubMed ID: 31227821
[No Abstract] [Full Text] [Related]
11. By the numbers. Drugs/purchasing.
Mod Healthc; 2003 Dec; Suppl():22. PubMed ID: 14723068
[No Abstract] [Full Text] [Related]
12. Public biotech 2010--the numbers.
Huggett B; Hodgson J; Lähteenmäki R
Nat Biotechnol; 2011 Jul; 29(7):585-91. PubMed ID: 21747381
[No Abstract] [Full Text] [Related]
13. The biotech drug market.
Lawrence S
Nat Biotechnol; 2004 Dec; 22(12):1496. PubMed ID: 15583645
[No Abstract] [Full Text] [Related]
14. Sunbaked biotechnology in Australia.
Littlejohn T
Nat Biotechnol; 2002 Sep; 20(9):873-7. PubMed ID: 12205502
[No Abstract] [Full Text] [Related]
15. Deconstructing Myogen's market cap.
Ransom J
Nat Biotechnol; 2006 Mar; 24(3):227-8. PubMed ID: 16525363
[No Abstract] [Full Text] [Related]
16. Insights into US public biotech sector using patenting trends.
Aggarwal S; Gupta V; Bagchi-Sen S
Nat Biotechnol; 2006 Jun; 24(6):643-51. PubMed ID: 16763590
[TBL] [Abstract][Full Text] [Related]
17. Public markets show signs of life.
Mitchell P
Nat Biotechnol; 2003 Aug; 21(8):833-4. PubMed ID: 12894181
[No Abstract] [Full Text] [Related]
18. Public companies get creative in raising finance.
Hodgson J
Nat Biotechnol; 2010 Apr; 28(4):301-2. PubMed ID: 20379161
[No Abstract] [Full Text] [Related]
19. The 802 million dollars fallacy.
Hodgson J
Nat Biotechnol; 2004 Sep; 22(9):1076. PubMed ID: 15340464
[No Abstract] [Full Text] [Related]
20. The origins of new drugs.
Kneller R
Nat Biotechnol; 2005 May; 23(5):529-30. PubMed ID: 15877061
[No Abstract] [Full Text] [Related]
[Next] [New Search]
